<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00162695</url>
  </required_header>
  <id_info>
    <org_study_id>RMS95</org_study_id>
    <nct_id>NCT00162695</nct_id>
  </id_info>
  <brief_title>Rhabdomyosarcoma and Malignant Soft Tissue Tumours of Childhood</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gustave Roussy, Cancer Campus, Grand Paris</source>
  <brief_summary>
    <textblock>
      Objective of the study objectives was to explore survival advantage for an intensified
      chemotherapy strategy in a randomised trial.

      IVA (ifosfamide, vincristine, actinomycin D) or a 6 drug combination (IVA + carboplatin,
      epirubicin, etoposide) both delivered over 27 weeks. Cumulative dose / m2 = ifosfamide 54g
      (both arms), epirubicin 450 mg, etoposide 1350 mg (6 drug). Delivery of radiotherapy was
      determined according to site and / or response to chemotherapy Â± surgery.

      The study was powered to detect 10% difference in 3 year OS.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>July 1995</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To explore survival advantage for an intensified chemotherapy strategy in a randomised trial</measure>
  </primary_outcome>
  <enrollment>400</enrollment>
  <condition>Rhabdomyosarcoma</condition>
  <condition>Malignant Soft Tissue</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ifosfamide, oncovin, actinomycine D, epirubicine, carboplatinum, etoposide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &gt; 6 months and &lt; 18 years

          -  no distant metastases

          -  diagnosis within previous 8 weeks without prior treatment except surgery

          -  pathology available for central review

          -  written consent according to institutional requirement

        Exclusion Criteria:

          -  stage III (node positive)

          -  stage I or II non alveolar orbital tumours

          -  patients with parameningeal disease aged &lt; 3 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Odile OBERLIN, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gustave Roussy, Cancer Campus, Grand Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael STEVENS, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital of Bristols, UK</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2005</study_first_submitted>
  <study_first_submitted_qc>September 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2005</study_first_posted>
  <last_update_submitted>September 9, 2005</last_update_submitted>
  <last_update_submitted_qc>September 9, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 13, 2005</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhabdomyosarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

